Wesseling J - Search Results

1

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, Shah V, Hoogstraat M, Sei E, Mallo D, Roman-Escorza M, Ahmed AA, Xu M, van den Belt-Dusebout AW, Brugman W, Casasent AK, Clements K, Davies HR, Fu L, Grigoriadis A, Hardman TM, King LM, Krete M, Kristel P, de Maaker M, Maley CC, Marks JR, Menegaz BA, Mulder L, Nieboer F, Nowinski S, Pinder S, Quist J, Salinas-Souza C, Schaapveld M, Schmidt MK, Shaaban AM, Shami R, Sridharan M, Zhang J, Stobart H, Collyar D, Nik-Zainal S, Wessels LFA, Hwang ES, Navin NE, Futreal PA; Grand Challenge PRECISION consortium; Thompson AM, Wesseling J, Sawyer EJ. Lips EH, et al. Among authors: wesseling j. Nat Genet. 2022 Jun;54(6):850-860. doi: 10.1038/s41588-022-01082-3. Epub 2022 Jun 9. Nat Genet. 2022. PMID: 35681052 Free PMC article.

2

p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.

de Roos MA, de Bock GH, de Vries J, van der Vegt B, Wesseling J. de Roos MA, et al. Among authors: wesseling j. J Surg Res. 2007 Jun 1;140(1):109-14. doi: 10.1016/j.jss.2006.10.045. Epub 2007 Feb 7. J Surg Res. 2007. PMID: 17291532 Free article.

3

The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.

van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J. van der Vegt B, et al. Among authors: wesseling j. Histopathology. 2007 Sep;51(3):322-35. doi: 10.1111/j.1365-2559.2007.02757.x. Epub 2007 Jul 23. Histopathology. 2007. PMID: 17645748 Free article.

4

The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.

de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J. de Roos MA, et al. Among authors: wesseling j. Histopathology. 2007 Aug;51(2):227-38. doi: 10.1111/j.1365-2559.2007.02754.x. Histopathology. 2007. PMID: 17650217

5

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S. de Ronde JJ, et al. Among authors: wesseling j. Breast Cancer Res Treat. 2010 Jan;119(1):119-26. doi: 10.1007/s10549-009-0499-6. Epub 2009 Aug 8. Breast Cancer Res Treat. 2010. PMID: 19669409

6

Aggressiveness of 'true' interval invasive ductal carcinomas of the breast in postmenopausal women.

van der Vegt B, Wesseling J, Pijnappel RM, Dorrius MD, den Heeten GJ, de Roos MA, de Bock GH. van der Vegt B, et al. Among authors: wesseling j. Mod Pathol. 2010 Apr;23(4):629-36. doi: 10.1038/modpathol.2009.188. Epub 2010 Jan 15. Mod Pathol. 2010. PMID: 20081807 Free article.

7

Molecular subtyping of breast cancer: ready to use?

de Ronde J, Wessels L, Wesseling J. de Ronde J, et al. Among authors: wesseling j. Lancet Oncol. 2010 Apr;11(4):306-7. doi: 10.1016/S1470-2045(10)70036-X. Lancet Oncol. 2010. PMID: 20359657 No abstract available.

8

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MTFD, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S. Lips EH, et al. Among authors: wesseling j. Ann Oncol. 2011 Apr;22(4):870-876. doi: 10.1093/annonc/mdq468. Epub 2010 Oct 11. Ann Oncol. 2011. PMID: 20937646 Free article.

9

Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.

Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM. Joosse SA, et al. Among authors: wesseling j. Genes Chromosomes Cancer. 2011 Feb;50(2):71-81. doi: 10.1002/gcc.20833. Genes Chromosomes Cancer. 2011. PMID: 21104783

10

Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.

Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WT, Wesseling J. Hartog H, et al. Among authors: wesseling j. Breast Cancer Res Treat. 2011 Oct;129(3):725-36. doi: 10.1007/s10549-010-1256-6. Epub 2010 Nov 24. Breast Cancer Res Treat. 2011. PMID: 21107683

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

371 results

Search Page